Medical Dosimetry
Volume 33, Issue 3 , Pages 234-238 , Autumn 2008

A Bland-Altman Analysis of the Bias Between Computed Tomography and Ultrasound Prostate Volume Measurements

Received 29 January 2007 ,Accepted 1 January 2008.

References 

  1. Wingo PA, Tong T, Bolden S. Cancer Statistics, 1995. CA Cancer J. Clin. 1995;45:8–30
  2. Mettlin C, Jones GW, Murphy GP. Trends in prostate cancer care in the United States, 1974–1990: Observations from the patient care evaluation studies of the American College of Surgeons Commission on Cancer. CA Cancer J. Clin. 1993;43:83–91
  3. Garfinkel L, Mushinski M. Cancer incidence, mortality and survival: Trends in four leading sites. Stat. Bull. Metrop. Insur. Co. 1994;75:19–27
  4. Prestidge BR, Prete JJ, Bucholz TA. A survey of current clinical practice of permanent prostate brachytherapy in the United States. Int. J. Radiat. Oncol. Biol. Phys. 1998;40:461–465
  5. Jemal A, Murray T, Samuels A. Cancer statistics 2003. CA Cancer. Clin. 2003;53:5–26
  6. Nag S, Ciezki JP, Cormack R, et al. Intraoperative planning and evaluation of permanent prostate brachytherapy: Report of the American Brachytherapy Society. Int. J. Radia. t Oncol. Biol. Phys. 2001;51:1422–1430
  7. Blasko JC, Mate T, Sylverter JE, et al. Brachytherapy for carcinoma of the prostate: Techniques, patient selection, and clinical outcomes. Semin. Radiat. Oncol. 2002;12:81–94
  8. Potters L, Cao Y, Calugaru E, et al. A comprehensive review of CT-based dosimetry parameters and biochemical control in patients treated with permanent prostate brachytherapy. Int. J. Radiat. Oncol. Biol. Phys. 2001;50:605–614
  9. Stock RG, Stone NN. Importance of post-implant dosimetry in permanent prostate brachytherapy. Eur. Urol. 2002;41:434–439
  10. Blasko JC, Wallner K, Grimm PD, et al. Prostate specific antigen based disease control following ultrasound guided 125iodine implantation for stage T1/T2 prostatic carcinoma. J. Urol. 1995;154:1096–1099
  11. Zietman AL, Coen JJ, Shipley WU, et al. Radical radiation therapy in the management of prostatic adenocarcinoma: The initial prostate specific antigen value as a predictor of treatment outcome. J. Urol. 1994;151:640–645
  12. Trapasso JG, deKernion JB, Smith RB, et al. The incidence and significance of detectable levels of serum prostate specific antigen after radical prostatectomy. J. Urol. 1994;152:1821–1825
  13. Badiozamani KR, Wallner K, Cavanagh W, et al. Comparability of CT-based and TRUS-based prostate volumes. Int. J. Radiat. Oncol. Biol. Phys. 1999;43:375–378
  14. Hoffelt SC, Marshall LM, Garzotto M, et al. A comparison of CT scan to transrectal ultrasound measured prostate volume in untreated prostate cancer. Int. J. Radiat. Oncol. Biol. Phys. 2003;57:29–32
  15. Bland JM, Altman DG. Statistical methods for assessing agreement between two methods of clinical measurement. Lancet. 1986;8:307–310Feb
  16. Al Rimawi M, Griffiths DJ, Boake RC, et al. Transrectal ultrasound versus magnetic resonance imaging in the estimation of prostatic volume. Br. J. Urol. 1994;74:596–600
  17. Sandler HM, Bree RL, McLaughlin PW, et al. Localization of the prostatic apex for radiation therapy using implanted markers. Int. J. Radiat. Oncol. Biol. Phys. 1993;27:915–919
  18. Park SB, Kim JK, Choi SH, et al. Prostate volume measurement by TRUS using heights obtained by transaxial and midsagittal scanning: Comparison with specimen volume following radical prostatectomy. Korean J. Radiol. 2000;1:110–113
  19. Milosevic M, Voruganti S, Blend R, et al. Magnetic resonance imaging (MRI) for localization of the prostatic apex: Comparison to computed tomography (CT) and urethrography. Radiother. Oncol. 1998;47:277–284
  20. Roach M, Faillace-Akazawa P, Malfatti C, et al. Prostate volumes defined by magnetic resonance imaging and computerized tomographic scans for three-dimensional conformal radiotherapy. Int. J. Radiat. Oncol. Biol. Phys. 1996;35:1011–1018

PII: S0958-3947(08)00033-2

doi: 10.1016/j.meddos.2008.01.001

Medical Dosimetry
Volume 33, Issue 3 , Pages 234-238 , Autumn 2008